| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 300122.CN | Chongqing Zhifei Biological Products Co. | 72.6 | $29,245 | CN |
| 300347.CN | Hangzhou Tigermed Consulting Co., Ltd. C | 63.7 | $13,068 | CN |
| 000661.CN | Changchun High & New Technology Industry | 71.3 | $11,439 | CN |
| 002603.CN | Shijiazhuang Yiling Pharmaceutical Co., | 65.6 | $7,265 | CN |
| 002821.CN | Asymchem Laboratories (Tianjin) Co., Ltd | 84.4 | $7,130 | CN |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| 600833.CN | Shanghai No. 1 Pharmacy Co. Ltd. Class A | 61.1 | $390 | CN |
| 300453.CN | Jiang Xi Sanxin Medtec Co Ltd Class A | 63.8 | $544 | CN |
| 300239.CN | Baotou Dongbao Bio-Tech Co., Ltd. Class | 67.0 | $603 | CN |
| 603309.CN | WELL LEAD MEDICAL CO LTD Class A | 64.3 | $734 | CN |
| 603998.CN | Hunan Fangsheng Pharmaceutical Co., Ltd. | 67.0 | $750 | CN |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| 000661.CN | Changchun High & New Technology Industry | 71.3 | 18 | CN |
| 600566.CN | HUBEI JUMPCAN PHARMACEUTICAL CO., LTD Cl | 71.0 | 14 | CN |
| 002252.CN | Shanghai RAAS Blood Products Co., Ltd. C | 62.9 | 13 | CN |
| 300482.CN | Guangzhou Wondfo Biotech Co., Ltd. Class | 74.3 | 11 | CN |
| 300122.CN | Chongqing Zhifei Biological Products Co. | 72.6 | 10 | CN |
| 000915.CN | Shandong Wit Dyne Health Co., Ltd. Class | 77.4 | 10 | CN |
| 300595.CN | Ovctek China, Inc. Class A | 63.6 | 10 | CN |
| 600867.CN | Tonghua Dongbao Pharmaceutical Co., Ltd. | 65.7 | 10 | CN |
| 600750.CN | Jiangzhong Pharmaceutical Co., Ltd. Clas | 52.7 | 8 | CN |
| 002737.CN | Sunflower Pharmaceutical Group Co., Ltd. | 66.4 | 8 | CN |
| Average Market Cap | $4,120 |
| Median Market Cap | $2,201 |
| Avg. 3 Mo. Dollar Vol. | $48,978,080 |
| Avg. 3 Mo. Trading Vol. | 11,156,541 |
| Last Rebalance Date | 12/12/2022 |
| Companies Replaced | 12 |
| Biggest Industry Increase | Health Care |
| Biggest Industry Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 20.2 |
| Forward P/E Ratio (12 Mo.) | 28.2 |
| Price/Book Ratio | 3.5 |
| Avg. Revenue Chg. - 3 Yr | 92.3% |
| Avg. Op. Income Chg. - 3 Yr. | 223.9% |
| Avg. EPS Growth - 3 Yr. | 36.7% |
| Avg. EPS Growth - 1 Yr. | 30.6% |
| Avg. Operating Margin | 22.6% |
| Avg. LT Debt to Total Capital | 8.5% |
| Avg. Return on Equity | 19.8% |
| Dividend Yield | 1% |
| MarketGrader China A-Shares Health Care 30 Index | 67.05 |
| China | 100.0% |
